BRCA1 and ovarian carcinoma: Given its close association with the BRCA1/2 genes and HR, it would be unsurprising if dynamic changes in expression with chemotherapy treatment were observed, and it is unexpected that its role in ovarian cancer chemoresistance has not already been further characterised, particularly as mutations have been shown to sensitize sarcoma tumours to PARP inhibitors [132].